Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: Evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model

Nephrology

Volumn 13, Issue 6, 2008, Pages 517-521

  Ohtomo, Shuichi ^a   Ito, Masaki ^b   Izuhara, Yuko ^a   Van Ypersele De Strihou, Charles ^d   Miyata, Toshio ^a,c  

^a TOKAI UNIVERSITY   (Japan)

^b CHARLES RIVER LABORATORIES   (United States)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Albuminuria; Angiotensin receptor blocker; Animal model; Calcium channel blocker; Diabetic nephropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN A1C; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; OLMESARTAN; UREA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIABETIC NEPHROPATHY; DISEASE COURSE; HYPERTENSION; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; TREATMENT OUTCOME; UREA BLOOD LEVEL;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; IMIDAZOLES; KIDNEY; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, IMMUNOLOGIC; SERPINS; TETRAZOLES;

EID: 52649095334     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00929.x     Document Type: Article

References (23)

1. Mogensen CE. Diabetes and hypertension. Lancet 1979 1:388 9.
2. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983 1:1175 9.
3. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001 135:73 87.
4. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 1996 334:939 45.
5. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001 345:870 8.
6. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002 106:672 8.
7. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998 339:1448 56.
8. Keane WF, Lyle PA. Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study. Am. J. Kidney Dis. 2003 41:S22 5.
9. Hunsicker LG, Atkins RC, Lewis JB et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int. Suppl. 2004 92:S99 101.
10. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 110:921 7.
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001 345:851 60.
12. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345:861 9.
13. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005 366:2026 33.
14. Mann JF, McClellan WM, Kunz R, Ritz E. Progression of renal disease: Can we forget about inhibition of the renin-angiotensin system? Nephrol. Dial. Transplant. 2006 21:2348 51.
15. Rossing P, Parving HH, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy: Fact or fiction? Nephrol. Dial. Transplant. 2006 21:2354 7.
16. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N. Engl. J. Med. 1997 337:536 42.
17. Breyer MD, Böttinger E, Brosius FC 3rd et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 2005 16:27 45.
18. Inagi R, Yamamoto Y, Nangaku M et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 2006 55:356 66.
19. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 2001 108:261 8.
20. Miyata T, Nangaku M, Suzuki D et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J. Clin. Invest. 1998 102:828 36.
21. Miyata T, Inagi R, Nangaku M et al. Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J. Clin. Invest. 2001 109:585 93.
22. Izuhara Y, Nangaku M, Inagi R et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 2005 16:3631 41.
23. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol. 2003 14:1212 22.